TERLIVAZ TERLIPRESSIN FOR INJECTION

Serial Number 88900093
Registration 7081079
700

Registration Progress

Application Filed
May 4, 2020
Under Examination
Nov 3, 2020
Approved for Publication
Sep 8, 2020
Published for Opposition
Sep 8, 2020
Registered
Jun 13, 2023

Trademark Image

TERLIVAZ TERLIPRESSIN FOR INJECTION

Basic Information

Serial Number
88900093
Registration Number
7081079
Filing Date
May 4, 2020
Registration Date
June 13, 2023
Published for Opposition
September 8, 2020
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 13, 2023
Registration
Registered
Classes
005

Rights Holder

MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED

24
Address
COLLEGE BUSINESS & TECHNOLOGY PARK
CRUISERATH ROAD, BLANCHARDSTOWN
DUBLIN 15 D15TX2V
IE

Ownership History

Mallinckrodt Hospital Products IP Limited

Original Applicant
99
Dublin 15 IE

Mallinckrodt Hospital Products IP Limited

Owner at Publication
99
Dublin 15 IE

MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED

New Owner After Publication #1
24
DUBLIN 15 IE

MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED

Original Registrant
24
DUBLIN 15 IE

Legal Representation

Attorney
Carlynn Ferguson

USPTO Deadlines

Next Deadline
1410 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-06-13)
Due Date
June 13, 2029
Grace Period Ends
December 13, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

35 events
Date Code Type Description Documents
Jun 13, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jun 13, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 9, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 7, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Mar 21, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jan 4, 2023 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Dec 28, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Nov 21, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 1, 2022 IUAF S USE AMENDMENT FILED Loading...
Nov 1, 2022 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Apr 6, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 4, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
Apr 4, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Apr 4, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 8, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 6, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Oct 6, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Oct 6, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 21, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 19, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 19, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 19, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 3, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 8, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 8, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 19, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 5, 2020 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Aug 5, 2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Aug 5, 2020 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Aug 5, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 5, 2020 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 29, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
May 16, 2020 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
May 15, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 7, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of hepatorenal syndrome (HRS)
First Use Anywhere: Oct 12, 2022
First Use in Commerce: Oct 12, 2022

Additional Information

Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TERLIPRESSIN FOR INJECTION"